The exchange token WBT from WhiteBIT reached a new all-time high of $83.64 on September 18, 2026, driven by a broad market rally including rate hikes by the US Federal Reserve and Bank of Japan. The rise reflects ongoing buyback-and-burn efforts and a technical upgrade to Whitechain's blockchain, anchoring WBT as the fee token on an Ethereum layer 2 network. Investors should note WBT's value depends on WhiteBIT's platform performance and regulatory compliance under EU MiCA rules, with tax implications for short-term gains in Germany. Liquidity is moderate, meaning large trades can significantly impact price, so caution is advised when trading large amounts.
The exchange token WBT from WhiteBIT reached a new all-time high of $83.64. For readers following the cryptocurrency sector, here is Pluang's market snapshot as of Sep 19, 2026 09:21 WIB: out of 50 major cryptocurrencies, 44 rose and 5 fell. Notable movers include UNI at Rp163.091 with a 16.27% increase and COTI at Rp369 with an 11.80% decrease.
Disc Medicine's stock surged 38% following positive Phase 3 trial results for its drug bitopertin, which showed efficacy and safety in treating erythropoietic protoporphyria. BMO Capital raised its price target from $100 to $120 and maintained an Out...
Qualcomm executive Ann C. Chaplin sold 1,827 shares of the company's stock for $319,268.25 under a Rule 10b5-1 trading plan, reducing her holdings by 6.62%. Qualcomm's stock price recently traded below its 50-day and 200-day moving averages, signalin...
BOK Financial is set to announce its Q3 2026 earnings after market close on October 19, with analysts forecasting earnings per share between $2.52 and $2.54 and revenue near $571 million. The company has a strong history of surpassing earnings estima...
AIBotics has completed the acquisition of NovaCore Labs' assets from PlayJamaica Limited, gaining technology, software, drones, mapping equipment, and customer contracts. This move expands AIBotics' platform in Jamaica and the Caribbean, enhancing AI...
EyePoint's stock dropped sharply after its DURAVYU treatment did not meet the primary endpoint in a Phase 3 trial for wet age-related macular degeneration (wet AMD). Although DURAVYU showed some vision improvement and reduced the need for additional ...
